Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single ascending dose study of ALKS 6610 in healthy adults
NL-OMON50062Phase 1Completed
- Sponsor
- Alkermes
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in pain comparing ALKS 6610 with Placebo (2 arms). Primary endpoints: Safety and tolerability endpoints and Pharmacokinetic endpoints. Started Jan 2020; status: completed.
02
Drugs
ALKS 6610
03
Conditions
pain
Beyond the preview
Go deeper on NL-OMON50062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50062.